125 Aufrufe 125 0 Kommentare 0 Kommentare

    New Results from AlzeCure's Pain Project TrkA-NAM Presented at the Pain Conference IASP 2024 - Seite 2

    The abstract and the poster are available on AlzeCure's website ( https://www.alzecurepharma.se/en/presentations-and-interviews/ ).

    For more information, please contact

    Martin Jönsson, CEO
    Tel: +46 707 86 94 43
    martin.jonsson@alzecurepharma.com

    About AlzeCure Pharma AB (publ)

    AlzeCure is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore, Alzstatin and Painless.

    NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

    FNCA Sweden AB is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .

    About TrkA-NAM
    The TrkA-NAM project, which is in research phase, is focused on the treatment of pain. The target mechanism, NGF / TrkA signaling, is well-validated both preclinically and clinically and provides a promising alternative to new analgesics without the side effects and addiction problems observed with opioids. Substances developed in the project have recently been shown to also have anti-inflammatory properties.

    For the TrkA-NAM drug project, we have leveraged our knowledge concerning the underlying biology for the NeuroRestore platform in order to develop new compounds that focus on providing pain relief in conditions associated with severe pain.

    The goal of the project is to develop a small-molecule TrkA-negative allosteric modulator for the treatment of osteoarthritis pain and other severe pain disorders. The global osteoarthritis market is expected to reach USD 11.0 billion by 2025, from USD 7.3 billion in 2020. Growth in this market is driven by factors such as the increasing occurrence of osteoarthritis, the growing aging population, and an increase in the number of sports injuries. Over 400 million people worldwide suffer from painful and activity-limiting osteoarthritis of the hip or knee. Many patients experience insufficient pain relief or side effects with current treatment, which today usually consist of NSAIDs or opiates and there is a great need for more effective and better tolerated drugs in this field.

    Image Attachments

    Martin Jönsson CEO And Pontus Forsell Head Of D&R AlzeCure Pharma

    Attachments

    New results from AlzeCure's pain project TrkA-NAM presented at the pain conference IASP 2024
    Pharmacological Effects Of ACD137, A Small Molecule Negative Allosteric Modulator Of TrkA TH719 IASP 2024 By AlzeCure Pharma

    SOURCE: AlzeCure Pharma



    View the original press release on accesswire.com

    Seite 2 von 2



    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen
    Verfasst von Accesswire
    New Results from AlzeCure's Pain Project TrkA-NAM Presented at the Pain Conference IASP 2024 - Seite 2 STOCKHOLM, SE / ACCESSWIRE / August 07, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on …